- Short Communication
- Open Access
Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors
Molecular and Cellular Pediatrics volume 5, Article number: 9 (2018)
β-Thalassemia is an inherited hematological disorder caused by mutations in the human hemoglobin beta (HBB) gene that reduce or abrogate β-globin expression. Although lentiviral-mediated expression of β-globin and autologous transplantation is a promising therapeutic approach, the risk of insertional mutagenesis or low transgene expression is apparent. However, targeted gene correction of HBB mutations with programmable nucleases such as CRISPR/Cas9, TALENs, and ZFNs with non-viral repair templates ensures a higher safety profile and endogenous expression control.
We have compared three different gene-editing tools (CRISPR/Cas9, TALENs, and ZFNs) for their targeting efficiency of the HBB gene locus. As a proof of concept, we studied the personalized gene-correction therapy for a common β-thalassemia splicing variant HBBIVS1–110 using Cas9 mRNA and several optimally designed single-stranded oligonucleotide (ssODN) donors in K562 and CD34+ hematopoietic stem cells (HSCs).
Our results exhibited that indel frequency of CRISPR/Cas9 was superior to TALENs and ZFNs (P < 0.0001). Our designed sgRNA targeting the site of HBBIVS1–110 mutation showed indels in both K562 cells (up to 77%) and CD34+ hematopoietic stem cells—HSCs (up to 87%). The absolute quantification by next-generation sequencing showed that up to 8% site-specific insertion of the NheI tag was achieved using Cas9 mRNA and a chemically modified ssODN in CD34+ HSCs.
Our approach provides guidance on non-viral gene correction in CD34+ HSCs using Cas9 mRNA and chemically modified ssODN. However, further optimization is needed to increase the homology directed repair (HDR) to attain a real clinical benefit for β-thalassemia.
β-Thalassemia (OMIM: 613985) is an inherited hematological disorder caused by mutations of the human hemoglobin beta (HBB) gene, leading to deficient β-globin expression and severe anemia . The current treatment options include allogeneic bone marrow transplantation and hematopoietic stem cell (HSC) transplantation but are limited to histo-compatible donors. However, gene therapy based on autologous transplantation of a lentiviral-transferred HBB gene to HSCs resulted in remarkable clinical benefit [2, 3]. Though the safety and efficacy of lentiviral-based gene therapy is positive in a treated patient, the transactivation of the proto-oncogene HMGA2 and more than 3500 unique integration sites in tested mouse model forewarns the possibility of insertional mutagenesis [2, 4]. Earlier retroviral gene therapy studies on other inherited diseases reported the treatment-related leukemogenesis [5,6,7], and lentiviral therapy resulted in T cell lymphoma in a mouse model of X-SCID due to random integration into oncogenes . Therefore, the ideal gene therapy with viral vectors must ensure targeted integration of a therapeutic HBB transgene in the endogenous locus. Otherwise, personalized gene-correction therapy with programmable nucleases and non-viral repair templates such as single-stranded oligonucleotides (ssODNs) must be employed as it is less likely to randomly integrate into the genome and result in a safe and precise gene editing . Though several studies targeted HBB gene with ZFNs, TALENs, and CRISPR/Cas9, no study has ever compared all the three gene-editing platforms simultaneously. Therefore, in the present study, we compared these three approaches for their target efficiency in parallel. Here, we tested the gene correction efficiency of strategically designed ssODNs as repair templates to target HBB gene. This is an important measure while editing the highly proliferating stem cell population to avoid clonal selection and thereby triggering oncogenesis.
First, we designed ZFNs, TALENs, and CRISPR/sgRNA for targeting the promoter region of the HBB gene (Additional file 1: Figure S1). The HBB gene-targeting efficacy of designed ZFNs, TALENs, or CRISPR/Cas9 was determined by T7 endonuclease-I (T7EI) assay in HEK293 cells. Interestingly, CRISPR/Cas9 exhibited higher indels for all three different concentrations (0.5 μg, 1.0 μg, and 1.5 μg) compared to ZFNs and TALENs (Fig. 1a; Additional file 1: Figure S1). Similar results were observed earlier for the HBBIVS2–654 mutation where gene-targeting efficiency of CRISPR/Cas9 was superior to TALENs . Therefore, we focused on CRISPR/Cas9 to examine the gene correction efficiency of non-viral repair templates. Several studies have targeted the HBB gene using CRISPR/Cas9 system in HSCs, induced pluripotent stem cells, and human embryos [11,12,13,14,15,16]. Most of these studies were either focused on HBB gene addition or targeting sickle cell disease mutation. To the best of our knowledge, this is the first study that attempted to target a common β-thalassemia splicing variant HBBIVS1–110 (rs35004220), which leads to an alternative splice site and reduced β-globin expression with a non-viral strategy .
To target the HBBIVS1–110 locus, we designed a sgRNA and several ssODNs (Fig. 1b; Additional file 1: Figure S1) with varying lengths of homology arms, symmetrical difference, and chemical modifications and complimentary to the strand targeted or not targeted by the guide-RNA . To evaluate the ability of CRISPR/Cas9 to correct the HBBIVS1–110 mutation by an exogenous DNA sequence, we introduced an NheI-tag (restriction site) into the ssODNs that can be stably integrated upon successful homology-directed repair (HDR) (Fig. 1b). We electroporated pX330.sg HBBIVS1–110 plasmid and ssODN donors harboring NheI-tag using a Neon system into K562 cells and evaluated the frequency of indels by T7EI assay and HDR-driven NheI integration by restriction fragment length polymorphism (RFLP) assay (Figs. 1c/d). Mean indel frequencies for the targeted loci were 44 ± 18%. We next determined whether any of the rationally designed ssODNs could stimulate gene targeting by HDR and found that most of the tested ssODNs resulted in similar HDR frequencies with the median of 20% (range 5–31%).
To assess our non-viral correction strategy with bone marrow-derived CD34+ HSCs, we co-delivered pX330.sg HBBIVS1–110 plasmid and several ssODNs. Unlike our results with K562 cells, the indel frequencies in HSCs were relatively low with a median of 30% (range 0–56%) and only one ssODN (5TS) exhibited 3% HDR rate in TIDE analysis (Fig. 2a; Additional file 1: Figure S3.A). We next sought to determine HDR rate for 5TS-ssODN by a semi-quantitative single-colony sequencing and found that 2% (3/172) of clones showed NheI insertions (Fig. 2b). We observed that pDNA resulted in lower transfection rate and higher cell death in HSCs (data not shown). Due to the low indel rate achieved by pDNA-encoded Cas9, we aimed to increase the efficiency and viability by using mRNA-encoded Cas9 as others and ourselves earlier reported the superiority of mRNA over pDNA [19,20,21]. In addition, transiently expressed Cas9 mRNA resulted in reduced off-targets compared to long-term Cas9 expression systems . Therefore, we delivered Cas9 mRNA and chemically modified sgRNA with four different ssODNs (chemically modified, 2 PAM-depleted, 5TS) using a 4D-Nucleofector. Genomic analysis with the T7EI assay resulted in high indels ranging from 65% (mod. ssODN) to 87% (11 NTS), and the RFLP assay showed up to 11% integration of NheI tag at the HBBIVS1–110 locus (Fig. 2c). Our results clearly imply the superiority of Cas9 mRNA over pDNA (Additional file 1: Figure S3.B). We noticed significant enrichment of 6-bp insertion (range 2–9%) by NheI integration at the target locus for tested ssODNs (Fig. 2d; Additional file 1: Figure S4).
However, the absolute quantification of site-specific insertion events of the NheI tag at the HBBIVS1–110 locus by next-Generation sequencing showed 8% correction for modified ssODN (Fig. 2e; Additional file 1: Figure S5). All the analyses spotted improved gene correction for chemically modified ssODN in HSCs as reported earlier . No detectable off-target cleavage was found in six of the in silico predicted off-targets (Additional file 2: Table S4; Additional file 1: Figure S6) for the sgRNA-targeted HBBIVS1–110 locus. We found that CRISPR/Cas9 greatly facilitates targeted genome modification compared to TALENs and ZFNs, and introduction of new DNA sequences in HSCs using Cas9 mRNA and ssODN is feasible without viral vectors. However, correction of 8% in HSCs at ex vivo setting is sub-optimal. Therefore, further improvement on HDR efficacy and selection of corrected cells is needed to attain a meaningful gene correction of HBB mutations to treat β-thalassemia and other related genetic diseases.
Design of gene-editing tools
The targeting efficacy at the promoter of the HBB gene locus (200 bp upstream of the transcription start site) between three different gene-editing tools (CRSIPR/Cas9, TALENs, and ZFN) was evaluated (Additional file 1: Figure S1). The ZFN constructs targeting the promoter were ordered from Sigma-Aldrich (http://www.sigmaaldrich.com). The full amino acid sequences of the ZFN pair are shown in Additional file 2: Data S1. The targeting TALEN pair was designed with the help of the online tool ZiFiT Targeter Version 4.2 (http://zifit.partners.org) and assembled by fast ligation-based automatable solid-phase high-throughput (FLASH). Plasmids encoding TALE repeats harboring different repeat variable di-residues (RVDs) with their FLASH IDs are summarized in Additional file 2: Table S1. The sgRNAs for promoter (5′-AGCCAGTGCCAGAAGAGCCA-3′) and HBBIVS1–110 (5-GGGTGGGAAAATAGACCAAT-3′) were designed using CRISPR design tool. The respective oligo pairs encoding the 20-nt guide sequences are annealed and ligated into a pX330 vector consisting of a SpCas9 expression cassette and a U6 promoter driving the expression of chimeric sgRNA. The chemically modified sgRNA for HBBIVS1–110 mutation was synthesized by incorporating 2-O-methyl 3′phosphorothioate (MS) modification at three terminal nucleotides at both the 5′ and 3′ ends.
Cell culture and transfection
HEK-293 cells were cultured in DMEM (https://www.thermofisher.com) supplemented with 10% FBS and 1% penicillin/streptomycin at 37 °C with 5% CO2. In HEK-293 cells, pDNA-encoded gene-editing tools (CRSIPR/Cas9, TALENs, and ZFN) were transfected using Lipofectamin 3000 at three different concentrations of 0.5, 1, and 1.5 μg. K562 cells were cultured in RPMI 1640 (https://www.thermofisher.com) supplemented with 10% FBS and 1% penicillin/streptomycin at 37 °C with 5% CO2. In K562 cells, 200 ng of pX330-Chimeric vector targeting HBBIVS1–110 loci was co-electroporated with 10 pmol of different ssODN using Neon Transfection System (https://www.thermofisher.com). Bone marrow-derived CD34+ HSCs from healthy donors were cultured in StemSpan™ serum-free medium II (SFEMII) containing StemSpan™ Cytokine Cocktail 110 (https://www.stemcell.com). 1 × 105 CD34+ HSCs were electroporated with 1.2 μg pX330 vector targeting HBBIVS1–110 mutation and 100 pmol of specified ssODN repair template using Lonza© 4D-Nucleofector™ (Program: EO 100). The similar amount of p.Max eGFP pDNA (1.2 μg) was electroporated as a transfection control. For Cas9 mRNA experiments, 1 × 105 CD34+ HSCs were co-electroporated with 5 μg chemically modified sgRNA, 10 μg Ca9 mRNA vector, and 100 pmol of specified ssODN repair template using Lonza© 4D-Nucleofector™ (Program: EO 100).
The ssODNs were synthesized by Metabion, Germany (www.metabion.com). The ssODNs were designed with an insertion site harboring an NheI recognition site (GCTAGC). The ssODNs were complimentary to either the strand targeted or not targeted by the gRNA, asymmetric or symmetric to the NheI tag. The chemically modified ssODN for HBBIVS1–110 mutation was synthesized by incorporating 2-O-methyl 3′phosphorothioate (MS) modification at three terminal nucleotides at both the 5′ and 3′ ends with 72 bp homology arms. The complete details can be found in Additional file 2: Table S2.
T7 endonuclease assay and RFLP assay
Five days post transfection, genomic DNA was isolated using Merchery-Nagel NucleoSpin Tissue Kit following the manufacturer’s instructions. The promoter region was amplified using the primer pair Prom-For_5′-GTAGACCACCAGCAGCCTAA-3′ and Prom-Rev_5′ TGGAGACGCAGGAAGAGATC-3′, and the region covering HBBIVS1–110 mutation was amplified using the primer pair IVS1–110-For_ 5′-GGGTTTGAAGTCCAACTCCTAA-3′ and 3′UTR-For_5′-AGAAAACATCAAGCGTCCCATA-3′. The target regions were amplified using the AmpliTag® Gold 360 MasterMix (https://www.thermofisher.com). The cycling parameters for both amplicons were as follows: initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s, and elongation at 72 °C for 1 min. PCR products were purified by ethanol precipitation, and 1 μg of PCR product was used for T7 endonuclease assay. Likewise, 1 μg of PCR product was used for the RFLP assay where amplicons bearing the NheI tag upon successful gene correction will result in a specific cleavage after the treatment with the NheI restriction enzyme. The readout of the T7 endonuclease assay and the RFLP assay were determined on a 1.5% agarose gel and on a Bioanalyzer chip using DNA1000 kit. The band intensities were quantified using ImageJ embedded in Fiji software (www.fiji.sc).
TIDE analysis and single-colony and next-generation sequencing
For analyzing allele modification frequencies with non-enzymatic assays, we used TIDE (Tracking of Indels by Decomposition) analysis by Sanger-sequencing the purified PCR products used for T7 assay and examined with the online TIDE software (http://tide.nki.nl.) with the respective control sample. To precisely measure the events of site-specific insertion of NheI tag at HBBIVS1–110 loci in CD34+ HSPCs, we performed two different approaches: (i) Sanger-based single-colony sequencing and (ii) next-generation sequencing. For single-colony sequencing, the HBBIVS1–110 region was PCR amplified from 5TS ssODN gene-corrected CD34+ HSCs and cloned into pJET1.2 vector using CloneJET PCR Cloning kit (https://www.thermofisher.com) and transformed into Top10 competent cells using standard cloning techniques. Closely, 192 (two 96-well plates) single colonies were processed for Sanger sequencing with pJET1.2 forward sequencing primer (5′-CGACTCACTATAGGGAGAGCGGC-3′) and analyzed for the presence for NheI recognition site (GCTAGC) using Geneious-R6 software. Three of 192 clones resulted in NheI insertion (1.5%). In case of next-generation sequencing (NGS), new primers were designed with the amplicon length of 150 bp to be sequenced with the Illumina platform (Forward 5′-AGAAACTGGGCATGTGGAGA-3′; Reverse 5′-CCATAACAGCATCAGGAGTGG-3′). Further, barcode-tagged PCR primers were used to multiplex samples (Additional file 2: Table S3), and are adapter ligated, size selected, and bridge amplified and proceeded with amplicon sequencing in HiSeq 4000 system (http://www.illumina.com). The standard R-Package was used for NGS analysis where the sequencing reads were pre-filtered for low-quality reads and mapped to the reference sequence using a BWA tool. Further, the number of indel-carrying sequence reads was calculated using SAM tools. The distribution plot was generated by calculating the size of the indels in sequence and calculating the median percentage for each indel class.
In vitro transcription (IVT) of Cas9 mRNA
The open reading frame of SpCas9 was PCR amplified from the pX330 vector and sub-cloned into the pVAX.120 vector consisting of a T7 promoter and 120 bp length of a poly-A tail using standard molecular biology techniques. The IVT reaction was performed in linearized plasmid using T7 RNA polymerase in MEGAscript T7 kit (https://www.thermofisher.com). All mRNAs were produced with an anti-reverse CAP analog (ARCA; [m7G(5′)G]) at the 5′ end (https://www.trilinkbiotech.com/). The IVT-mRNAs were made with following chemical modifications in the indicated ratios: 100% Pseudo-UTP and 25% s2-thio-UTP/5-methyl-CTP (https://www.trilinkbiotech.com/). All IVT mRNAs were purified using the MEGAclear kit (https://www.thermofisher.com) and quantified with nano-photometer and bioanalyzed for quality using the RNA6000 kit in Agilent 2100 Bioanalyzer (https://www.agilent.com).
Kruskal-Wallis or Wilcoxon-Mann-Whitney rank-sum tests were applied wherever appropriate to analyze the differences in indel induction among the gene-editing technologies and comparison between encoded pDNA Cas9 and Cas9 mRNA using Graphpad Prism v.6.0d (https://www.graphpad.com).
Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61–76. https://doi.org/10.1097/GIM.0b013e3181cd68ed
Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chretien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chretien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467(7313):318–322. https://doi.org/10.1038/nature09328
Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S, Hongeng S, Hacein-Bey S, Cavazzana M, Leboulch P, Payen E (2016) Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(a(T87Q))-globin gene. Hum Gene Ther 27(2):148–165. https://doi.org/10.1089/hum.2016.007
Ronen K, Negre O, Roth S, Colomb C, Malani N, Denaro M, Brady T, Fusil F, Gillet-Legrand B, Hehir K, Beuzard Y, Leboulch P, Down JD, Payen E, Bushman FD (2011) Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat beta-thalassemia. Mol Ther 19(7):1273–1286. https://doi.org/10.1038/mt.2011.20
Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, Modlich U, Beier R, Gohring G, Steinemann D, Fronza R, Ball CR, Haemmerle R, Naundorf S, Kuhlcke K, Rose M, Fraser C, Mathias L, Ferrari R, Abboud MR, Al-Herz W, Kondratenko I, Marodi L, Glimm H, Schlegelberger B, Schambach A, Albert MH, Schmidt M, von Kalle C, Klein C (2014) Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med 6(227):227ra233. https://doi.org/10.1126/scitranslmed.3007280
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644):415–419. https://doi.org/10.1126/science.1088547
Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Luthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12(4):401–409. https://doi.org/10.1038/nm1393
Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM (2006) Gene therapy: therapeutic gene causing lymphoma. Nature 440(7088):1123. https://doi.org/10.1038/4401123a
Steyer B, Bu Q, Cory E, Jiang K, Duong S, Sinha D, Steltzer S, Gamm D, Chang Q, Saha K (2018) Scarless genome editing of human pluripotent stem cells via transient puromycin selection. Stem Cell Rep. https://doi.org/10.1016/j.stemcr.2017.12.004
Xu P, Tong Y, Liu XZ, Wang TT, Cheng L, Wang BY, Lv X, Huang Y, Liu DP (2015) Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in beta-thalassemia-derived iPSCs. Sci Rep 5:12065. https://doi.org/10.1038/srep12065
Cai L, Bai H, Mahairaki V, Gao Y, He C, Wen Y, Jin YC, Wang Y, Pan RL, Qasba A, Ye Z, Cheng L (2018) A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease. Stem Cells Transl Med 7(1):87–97. https://doi.org/10.1002/sctm.17-0066
Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH (2016) CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 539(7629):384–389. https://doi.org/10.1038/nature20134
Huang X, Wang Y, Yan W, Smith C, Ye Z, Wang J, Gao Y, Mendelsohn L, Cheng L (2015) Production of gene-corrected adult Beta globin protein in human erythrocytes differentiated from patient iPSCs after genome editing of the sickle point mutation. Stem Cells 33(5):1470–1479. https://doi.org/10.1002/stem.1969
Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J (2015) CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5):363–372. https://doi.org/10.1007/s13238-015-0153-5
Niu X, He W, Song B, Ou Z, Fan D, Chen Y, Fan Y, Sun X (2016) Combining single strand oligodeoxynucleotides and CRISPR/Cas9 to correct gene mutations in beta-thalassemia-induced pluripotent stem cells. J Biol Chem 291(32):16576–16585. https://doi.org/10.1074/jbc.M116.719237
Tang L, Zeng Y, Du H, Gong M, Peng J, Zhang B, Lei M, Zhao F, Wang W, Li X, Liu J (2017) CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. Mol Gen Genomics 292(3):525–533. https://doi.org/10.1007/s00438-017-1299-z
Thein SL (2013) The molecular basis of beta-thalassemia. Cold Spring Harb Perspect Med 3(5):a011700. https://doi.org/10.1101/cshperspect.a011700
Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE (2016) Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol 34(3):339–344. https://doi.org/10.1038/nbt.3481
Antony JS, Dewerth A, Haque A, Handgretinger R, Kormann MS (2015) Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies. Mol Cell Pediatr 2(1):11. https://doi.org/10.1186/s40348-015-0022-6
Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33(9):985–989. https://doi.org/10.1038/nbt.3290
Mahiny AJ, Dewerth A, Mays LE, Alkhaled M, Mothes B, Malaeksefat E, Loretz B, Rottenberger J, Brosch DM, Reautschnig P, Surapolchai P, Zeyer F, Schams A, Carevic M, Bakele M, Griese M, Schwab M, Nurnberg B, Beer-Hammer S, Handgretinger R, Hartl D, Lehr CM, Kormann MS (2015) In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat Biotechnol 33(6):584–586. https://doi.org/10.1038/nbt.3241
Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S, Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA, Langer R, Xue W, Anderson DG (2016) Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 34(3):328–333. https://doi.org/10.1038/nbt.3471
Renaud JB, Boix C, Charpentier M, De Cian A, Cochennec J, Duvernois-Berthet E, Perrouault L, Tesson L, Edouard J, Thinard R, Cherifi Y, Menoret S, Fontaniere S, de Croze N, Fraichard A, Sohm F, Anegon I, Concordet JP, Giovannangeli C (2016) Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPR-Cas9 nucleases. Cell Rep 14(9):2263–2272. https://doi.org/10.1016/j.celrep.2016.02.018
We thank Mr. Brian Weidensee for the help with the proofreading of the draft.
This work was supported by the Sanitätsrat Dr. Alexander Huebner und Gemahlin-Stiftung and by the UKT-fortüne grant (no. 2412-0-0). J.S.A. was financially supported by UKT-fortüne grant (to J.S.A., No. 2485-0-0) and Europe Research Council Starting Grant-ERC StG (to M.S.D.K., No. 637752). NL was supported by HMZ Private Foundation (to M.S.D.K). A.H. was supported by ERC StG (to M.S.D.K., No. 637752). A.L.C. was supported by Jürgen Man-chot-Stiftung. A.D.M. was supported by a UKT-fortüne grant (to M.M., No. 2412-0-0). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its Additional files).
Ethics approval and consent to participate
Ethical approval for using CD34+ hematopoietic stem cells from healthy donors was obtained from Ethics commission, University Clinic of Tuebingen, Germany (829/2016BO2).
Consent for publication
M.S.D.K. is listed as main inventor on a patent application related to Nuclease encoding modified mRNA. M.S.D.K. is a main inventor on a patent licensed to the biopharmaceutical company, Ethris GmbH. M.S.D.K., A.D., A.H., and J.S.A. are inventors (with M.S.D.K. as main inventor) on a patent application related to modified mRNA encoding hCFTR.
Figure S1. Strategy for targeting the promoter and IVS1–110 mutation of the HBB gene. A) The promoter region of HBB gene targeted with three different gene-editing tools, HBBIVS1–110 targeted with CRISPR/Cas9. B) The design of three different gene-editing tools at sequence level. Figure S2 Comparison of three different gene-editing tools at HBB promoter. The complete raw data of Fig. 1a. Figure S3 Gene correction of HBBIVS1–110 in CD34+ HSCs using pX330.sg HBBIVS1–110 and ssODNs. A) CD34+ HSCs nucleofected with pX330.sg HBBIVS1–110 plasmid and ssODNs and measured for indel rate by T7 assay and HDR by TIDE analysis. Only 5TS resulted 3% HDR rate in TIDE analysis (as in Fig. 2a). B) Gene-editing capacity of pDNA-encoded Cas9 and mRNA-encoded Cas9 were compared, and superiority of Cas9 mRNA was observed (P < 0.0001). Figure S4 TIDE analysis-gene correction of HBBIVS1–110 in CD34+ HSCs using Cas9 mRNA and ssODNs. TIDE analyses of four different ssODNs resulted in varying levels of 6 bp insertions that rely with the ssODN design. Modified ssODN resulted up to 8% HDR rate. Figure S5 NGS analysis-gene correction of HBBIVS1–110 in CD34+ HSCs using Cas9 mRNA and ssODNs. The absolute quantification of NheI insertion by NGS analyses for four different ssODNs showed distinct rate of 6 bp insertions and correlate with ssODN design. Modified ssODN resulted up to 8% HDR rate. Figure S6 Off-target analysis for the in silico predicted sites. The indel rate was measured by T7 endonuclease-I (T7EI) assay for six different off-target sites predicted through in silico (Additional file 2: Table S4) in K562 cells. We preselected top three hits in intronic and three hits in an exonic region. (PDF 2219 kb)
Data S1 The complete amino acid sequences of the HBB targeting ZFNs. Table S1 TALE FLASH IDs and RVDs targeting the promoter of HBB gene. Table S2 Details of ssODNs (sequence, symmetry, and length of homology arms). Table S3 Barcode and sample details of next-generation sequencing. Table S4 Details of off-target position, primer details, and indel frequency. (PDF 601 kb)
About this article
Cite this article
Antony, J.S., Latifi, N., Haque, A.K.M.A. et al. Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors. Mol Cell Pediatr 5, 9 (2018). https://doi.org/10.1186/s40348-018-0086-1
- Gene correction
- Cas9 mRNA